Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Fineline Cube Mar 5, 2026
Company Drug

Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Fineline Cube Mar 9, 2026
Company Drug

Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers

Fineline Cube Mar 9, 2026
Company Drug

Wepon Medical’s WP107 Receives FDA Approval for gMG Clinical Trial

Fineline Cube Jan 16, 2025

China-based Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced receiving clinical trial approval...

Company Drug

Fosun Pharma Initiates Phase II Study for Glomerular Disease Treatment

Fineline Cube Jan 16, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...

Company Drug

Hengrui’s SHR-9839 Receives NMPA Clearance for Advanced Tumors

Fineline Cube Jan 16, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical clearance from the...

Legal / IP

Chipscreen’s Epidaza Patent Faces Invalidation Request Review

Fineline Cube Jan 16, 2025

China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request...

Company Deals

Biogen Proposes to Acquire Sage Therapeutics for $469M

Fineline Cube Jan 15, 2025

US-based Sage Therapeutics, Inc. (NASDAQ: SAGE) has announced that it received an unsolicited, nonbinding proposal...

Company Deals Medical Device

Medtronic Secures Exclusive Distribution Rights for Contego’s Neuroguard and Excipio

Fineline Cube Jan 15, 2025

US-Irish firm Medtronic (NYSE: MDT) has entered into an exclusive distribution agreement with Contego Medical,...

Company Deals

Eli Lilly to Acquire Scorpion Therapeutics’ STX-478 for $2.5B

Fineline Cube Jan 15, 2025

US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from...

Company Deals

Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6B

Fineline Cube Jan 15, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) is set to acquire all outstanding shares of...

Company Deals

GSK Acquires IDRx for $1B to Boost GIST Treatment Pipeline

Fineline Cube Jan 15, 2025

UK-headquartered GlaxoSmithKline (GSK; NYSE: GSK) has entered into an agreement with US-based biopharma IDRx, Inc....

Company Deals

Autobio Diagnostics Partners with Boditech Med for Korean IVD Market

Fineline Cube Jan 15, 2025

China-based Autobio Diagnostics Co., Ltd (SHA: 603658) has announced a strategic partnership with South Korea-headquartered...

Company Deals

Henlius and Abbott Sign License Agreement for Biosimilars and Biologic Drug

Fineline Cube Jan 15, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced a strategic license agreement with Abbott...

Company Drug

Chongqing Genrix’s Silevimig NDA Accepted for Rabies Immunization Review

Fineline Cube Jan 15, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) has announced that a New Drug...

Legal / IP

Novartis to Defend Entresto Patent After CAFC Ruling

Fineline Cube Jan 14, 2025

Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for...

Company Deals

Bristol-Myers Squibb Exercises License for ArsenalBio’s AB-4000 Series

Fineline Cube Jan 14, 2025

US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY)...

Company Drug

Hengrui and Kailera Announce Positive Phase II Results for HRS9531 in Weight Loss

Fineline Cube Jan 14, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc....

Company Deals

Gentize Biopharma Raises $13.64M in Pre-Series A for Vaccine Development

Fineline Cube Jan 14, 2025

Gentize Biopharma, a clinical-stage vaccine developer based in Nanjing, has reportedly raised close to RMB...

Company Medical Device

Roche’s VENTANA Kappa and Lambda Dual ISH Test Gains FDA Clearance

Fineline Cube Jan 14, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that it has received marketing...

Company Deals

Illumina Partners with NVIDIA to Advance Multiomic Data Analysis

Fineline Cube Jan 14, 2025

US-based genomics giant Illumina (NASDAQ: ILMN) has announced a strategic partnership with chip manufacturer NVIDIA...

Company Drug

Leqembi Autoinjector Advances with FDA Review for Alzheimer’s Treatment

Fineline Cube Jan 14, 2025

Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that the...

Company Deals

Mediar Therapeutics and Eli Lilly Ink Deal for IPF Drug MTX-463

Fineline Cube Jan 14, 2025

US-based clinical-stage biotech Mediar Therapeutics, Inc. has announced a global license agreement with Eli Lilly...

Posts pagination

1 … 192 193 194 … 632

Recent updates

  • Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis
  • Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets
  • Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers
  • Leads Biolabs’ Opamtistomig Enters Phase II in First-Line Esophageal Cancer – PD-L1/4-1BB Bispecific with BTD/ODD Designations
  • CSPC’s SYH2059 Inhalation Powder Wins FDA IND Approval – PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Company Drug

Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers

Company Drug

Leads Biolabs’ Opamtistomig Enters Phase II in First-Line Esophageal Cancer – PD-L1/4-1BB Bispecific with BTD/ODD Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.